Portfolio Company Update: Artios Pharma

RTW Biotech Opportunities Ltd

12 April 2024

 

LEI: 549300Q7EXQQH6KF7Z84

12 April 2024

RTW Biotech Opportunities Ltd

Portfolio Company Update: Artios Pharma

●	RTW's, Chris Liu PhD, joins the Artios Pharma Board of Directors
●	The Company's holding in Artios Pharma was significantly increased with the recent Arix transaction, making it one of the top shareholders

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to announce that Chris Liu, PhD has been appointed to the Board of Directors at Artios Pharma ("Artios"). Chris is a Senior Research Analyst at RTW Investments, LP (the "Investment Manager") where he leads oncology research efforts.

In February 2024, RTW Biotech Opportunities acquired the assets of Arix Bioscience, plc, of which Artios Pharma was the largest position. The transaction significantly added to the Company's existing position in Artios. At 31 March 2024, Artios represented 4.6% of the Company's NAV.

Artios is a Cambridge, UK-based company developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to specifically destroy certain devastating cancers that are difficult to treat.

Chris Liu, PhD, commented: "RTW is now a top shareholder of Artios following the acquisition of Arix. The expansion of our equity interest reflects our confidence and excitement in Artios' innovative platform targeting broad aspects of the DNA damage response. I look forward to partnering with the team and the Board to support them in their mission to bring new therapies to patients suffering from difficult to treat solid tumors."

Artios' announcement can be found on their website: https://artios.com/.

For Further Information

RTW Investments, LP	[phone]
Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations	[e-mail]
Buchanan (PR & Communications Adviser)	[phone]
Charles Ryland
Henry Wilson
George Beale
Deutsche Numis (Joint Corporate Broker)	[phone]
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities (Joint Corporate Broker)	[phone]
Edward Peel
Alex Penney
Cadarn Capital (Distribution & IR Partner)	[phone]
David Harris
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director	[phone]
Morgan Stanley Fund Services USA LLC	[phone]

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

 

END